. In contrast, the survival of patients with chronic granulocytic leukaemia (C.G.L.) remains little better than that observed 50 years ago in untreated patients (Minot et al., 1924) . In one controlled trial half of all patients receiving busulphan were dead within 170 weeks of beginning treatment, while patients receiving radiotherapy fared significantly worse (Medical Research Council, 1968) . In over 70% of patients in the M.R.C.'s trial death was due to uncontrolled leukaeniia. The disease underwent a change best described as metamorphosis (Baikie, 1969) in which the features of C.G.L. in its chronic phase were partly or wholly lost and the neoplasm behaved in a more malignant fashion. Metamorphosis of C.G.L. has many variants, with refractoriness to previously effective therapy as their only common denominator, but in about half the cases in the M.R.C. series the process was characterized by the accumulation of primitive cells in the bone marrow and peripheral blood and an acute couTse terminating within six months. This picture is usually termed acute transformation of C.G.L. and its most rapidly progressive form, with sudden onset and very rapid deterioration, used to be termed "blastic crisis" and is easily recognized though fortunately relatively uncommon.
Two major factors limit survival in C.G.L. Conventional therapy for the chronic phase, usually with busulphan, improves the quality of life but fails to postpone substantially the onset of metamorphosis. Treatment for metamorphosis, particularly when of the acute transformation type, is unsatisfactory and has had no significant effect on the median survival. Prolonged deferment of metamorphosis would improve the prognosis in C.GL. and this is being attempted -for example, by active immunotherapy during the chronic phase (Sokal et al., 1973 Case 2.-The blast cells cleared from this patient's peripheral blood, splenomegaly regressed, and her symptoms were abolished. Her response was good, and she was able to travel extensively between the 12 courses of treatment she was given. Her leukaemia finafly became progressively more resistant and after more intensive TRAMPCO therapy she succumbed with septicaemia and renal failure eight months after transformation.
Case 3.-The partial response of this woman consisted in prompt and complete regression of splenomegaly, blasts cleared from peripheral blood with the first oourse and did not return, and her symptoms improved. Three courses of TRAMPCO were given. The platelet count imiproved but did not become normal, and transfusions were necessary to maintain haemoglobin, buit she was able to live at home. She eventually died four months after transformation from klebsiella septicaemia.
Case 4.-The response in this patient was haematological only. After one course of treatment peripheral blood cleared of blast cells, but she died with a pulmonary embolus before the second course was due, having survived three months of transformation.
Case 5.-There was a rapid fall of blast cells after each treatment in this patient with haematological res,ponse but an equally rapid return to high values. There was some relief of symptoms. Doses were escalated on successive courses and neutropenia and thrombocytopenia were severe. She died of hypostatic pneumonia three months after transformation and shortly after the third course of TRAMPGO(L).
Case 6.-The response of this patient was haematologicalionly. Splenectomy was performed before TRAMPCO(L) was begun. Postoperatively blast cells feld and neutrophils and platelets rose. The first course of TRAMPCO(L) caused a 90% fall in blast cells with no decline in neutrophils or platelets, but the patient died of bilateral bronchopneumonia before the second course, having survived transformation for three months.
Case 7.-A good response in this patient resulted in an immediate complete regression of 9-cm splenomegaly and gross cervical lymphadenopathy. Abnormal monocytoid blast cells cleared from peripheral blood and reduced to 10% in bone marrow. Clinical improvement was sufficient to justify a splenectomy. Since the splenectomy he has been working and has maintained a normal blood count without transfusion. He has had six courses of TRAMPCO-the last three at three-month intervals-and radiotherapy for recurrent cervical lymphadenopathy. At the time of this report he was alive and well, over 12 months after the start of transformition.
Case 8.-The response in this -patient was haematological only. The blast cell oDunt fell but rebounded after each of two courses of TRAMPCO. Nevertheless, symptoms attributable to uncontrolled leukaemia were relieved. Severe oral moniliasis and bacterial glossitis precluded further therapy with drugs likely to exacerbate his sto=mtitis, so TRAMPCO was abandoned. At the time of this report he had survived transformtion for over two months.
Case 9.-After the first course of TRAMPCO the response in this patient was good, and blast cells cleared from peripheral blood. His bone marrow became less cellular and previous excess of prinmitive cells was no longer present. The patient lived at home, and had normal platelet and neutrophil counts: haemoglobin was 10 g/ 100 mi, and he has had no -blood transfusion at any stage. He was alive at the time of this report, over three months after the start of transformation.
In the only patient with "agranular" blast cells (case 3) the peripheral blast cell count had fallen with prednisolone and vincristine, but splenonegaly and marrow hypercellularity with 80% of primitive cells persisted. Major improvement resulted from TRAMPCO(L) therapy with complete regression of 5-cm splenomegaly, but transfusions were still needed and response was rated as partial. Survival in the four patients achieving a good response was unexpectedly long considering the acute onset and rapid progression of metamorphosis in each. Prolonged survival and absence of pancytopenia in case 1 seemed possibly related to the previous splenectomy; for this reason splenectomy was performed before TRAMPCO(L) was begun in case 6. The patient in case 7 was splenectomized after an excellent response to chemotherapy. The operation was uncomplicated and it is hoped that the absence of a spleen will ameliorate his future course. This patient, a professional man, was in active practice at the time of writing. TOXICITY Though inspection of the TRAMPCO(L) schedule (see table IV) suggests that the toxicity of this regimen might be extreme this was not the case. Nausea and vomiting occurred in six patients, but it was severe and protracted only in the three patients who received colaspase (TRAMPCO(L)). In six patients the colaspase was omitted (TRAMPCO). Three patients had mouth ulcers and one had considerable alopecia. Pancytopenia occurred in all patients but was not more severe than had been observed in patients treated with only two to four drugs. In most patients it was in fact possible to make one or more increments in dosage on successive courses of TRAMPCO(L). Steroid side effects were unconmnon; the steroid dose was high but maintained for only five days, with intervals of 2-12 weeks (mean three weeks) between courses. No patient refused to continue therapy with TRAMPCO(L).
Discussion
The results of treatment in our first 43 patients confirm the widespread impression that acute transformation of C.G.L. rarely responds to steroids or mercaptopurine. No complete remissions occurred in seven patients who received prednisolone and vincristine. The more elaborate drug combinations used in the next eight patients possessed no clear advantage over the earlier treatments. The use of seven or eight drugs in combination (TRAMPCO or TRAMPCO(L)), however, in nine patien-ts produced four unexpectedly satisfactory responses with a mean survival of more than nine months. All nine patients had rapidly progressive acute transformation of C.G.L. and most were seriously ill when treatment began. The only patient with "agranular" blast cells did not have a satisfactory response to treatment. Three of the four patients who achieved a good response with TRAMPCO(L) had failed to respond to other regimens which have been advocated for acute transformation.
These results can only be regarded as prelininary. Nevertheless, the TRAMPC(L) regimen is acceptable to patients and toxicity is not prohibitive. The responses produced in acute transformation of C.G.L. were of good quality and of a duration unusual in this disease. While the less aggressive combination of prednisolone with vincristine may be preferred for the initial treatment of acute transformation some 70% of patients will not respond and in these the TRAMPCO(L) regimen should be tried.
